581 related articles for article (PubMed ID: 23076950)
1. Venom immunotherapy for preventing allergic reactions to insect stings.
Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.
Hockenhull J; Elremeli M; Cherry MG; Mahon J; Lai M; Darroch J; Oyee J; Boland A; Dickson R; Dundar Y; Boyle R
Health Technol Assess; 2012; 16(12):III-IV, 1-110. PubMed ID: 22409877
[TBL] [Abstract][Full Text] [Related]
3. Specific allergen immunotherapy for the treatment of atopic eczema.
Tam H; Calderon MA; Manikam L; Nankervis H; García Núñez I; Williams HC; Durham S; Boyle RJ
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008774. PubMed ID: 26871981
[TBL] [Abstract][Full Text] [Related]
4. The value of immunotherapy with venom in children with allergy to insect stings.
Valentine MD; Schuberth KC; Kagey-Sobotka A; Graft DF; Kwiterovich KA; Szklo M; Lichtenstein LM
N Engl J Med; 1990 Dec; 323(23):1601-3. PubMed ID: 2098016
[TBL] [Abstract][Full Text] [Related]
5. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
6. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of a Progressively Prolonged Maintenance Interval of Venom Immunotherapy.
Kontou-Fili K; Pitsios C; Kompoti E; Giannakopoulos D; Kouridakis S
Int Arch Allergy Immunol; 2018; 176(1):39-43. PubMed ID: 29649812
[TBL] [Abstract][Full Text] [Related]
8. Continuous immunotherapy for hymenoptera venom allergy using six month intervals.
Baenkler HW; Meusser-Storm S; Eger G
Allergol Immunopathol (Madr); 2005; 33(1):7-14. PubMed ID: 15777517
[TBL] [Abstract][Full Text] [Related]
9. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings.
Ewan PW; Deighton J; Wilson AB; Lachmann PJ
Clin Exp Allergy; 1993 Aug; 23(8):647-60. PubMed ID: 8221268
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
11. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
[TBL] [Abstract][Full Text] [Related]
12. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
[TBL] [Abstract][Full Text] [Related]
13. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
[TBL] [Abstract][Full Text] [Related]
14. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous venom immunotherapy in children: Efficacy and safety.
Gür Çetinkaya P; Esenboğa S; Uysal Soyer Ö; Tuncer A; Şekerel BE; Şahiner ÜM
Ann Allergy Asthma Immunol; 2018 Apr; 120(4):424-428. PubMed ID: 29625665
[TBL] [Abstract][Full Text] [Related]
16. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
Goldberg A; Confino-Cohen R
J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of immunotherapy with aluminum hydroxide-adsorbed venom extract of Vespula spp. An open, retrospective study.
Poli F; Longo G; Parmiani S
Allergol Immunopathol (Madr); 2001; 29(5):191-6. PubMed ID: 11720652
[TBL] [Abstract][Full Text] [Related]
18. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
19. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
[TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Seitz MJ; Aberer W; Bodzenta-Lukaszyk A; Bonifazi F; Campi P; Darsow U; Haeberli G; Hawranek T; Küchenhoff H; Lang R; Quercia O; Reider N; Schmid-Grendelmeier P; Severino M; Sturm GJ; Treudler R; Wüthrich B
PLoS One; 2013; 8(5):e63233. PubMed ID: 23700415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
